Skip to main content

Dx Focus Jun 3, 2010: Clinical and Regulatory PCR and Nucleic Acid Testing News


BD Diagnostics has received 510(k) clearance from the US Food and Drug Administration to market its BD Max GBS Assay for Group B Streptococcus on the PCR-based BD Max System.

The current standard of care for prevention of prenatal GBS disease is by screening pregnant women at 35 to 37 weeks by using cultures. Such methods, however, have limited sensitivity, long turnaround time, and depend on highly trained staff to interpret the results, BD said in a statement.

The new assay on the BD Max system can identify GBS in about one hour in Lim broth, and because it automates sample lysis through PCR, the system can analyze up to 24 samples in about two and a half hours, the company said.

"As new [Centers for Disease Control and Prevention] guidelines emerge to include molecular testing as an alternative to culture for detecting GBS, the BD Max GBS assay could serve as an efficient, sensitive, and specific option for laboratories desiring to utilize a molecular method," said Steve Young, scientific director for microbiology and virology at TriCore Reference Laboratories, in a statement.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.